Pulse Biosciences, Inc. (PLSE) stock analysis
Healthcare · Medical Instruments & Supplies
From the 10-K filed 2026-02-19
Business type: Asset play
How it makes money
It has not generated significant revenue and relies on external financing to fund operations while attempting to commercialize its proprietary nPulse System.
The company operates as a novel ablation business focused on health innovation using patented Nano-pulse Stimulation technology. To date, it has not generated significant revenue and has historically relied on financing from the sale of equity securities and loans to fund its operations. Future financial results depend primarily on its success in launching, selling, and supporting therapies and procedures using its technology.
What protects it: the moat
It relies on patented Nano-pulse Stimulation technology and proprietary system design, though management asserts that its ongoing efforts will secure competitive advantages.
The company bases its technological approach on patented Nano-pulse Stimulation technology delivering nanosecond-duration pulses of electrical energy. It developed a proprietary nPulse System delivery platform and designed a variety of applicators or disposables for various medical specialties. Because the business is in early commercial stages, much of its long-term defensibility rests on management's claims regarding future regulatory clearances and market adoption.
What growth costs
It expects to expend significant resources on personnel hiring, research and development, clinical investigations, intellectual property prosecution, working capital, and capital expenditures.
The company incurs continuous operating losses and expects to spend heavily on consulting costs, laboratory development, hiring of scientists, engineers, sales representatives, and other operational personnel. Reinvestment is also directed toward clinical trials, such as the PRECISE BTN clinical trial evaluating up to 50 patients at up to four sites, alongside regulatory submissions and capital raising efforts.
What could damage it
If clinical trials fail to demonstrate adequate efficacy or safety, or if regulatory clearances are delayed, it cannot commercialize products, destroying its revenue prospects.
The company depends entirely on proving the safety and effectiveness of its novel ablation technology through clinical trials and securing regulatory clearances such as FDA 510(k) approvals. If trials fail or regulatory bodies reject applications, the company cannot market its devices, leading to permanent impairment of its business model and inability to recover research and development expenses.
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.